MED — Medifast Income Statement
0.000.00%
- $134.97m
- -$27.37m
- $602.46m
- 99
- 96
- 42
- 94
Annual income statement for Medifast, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 935 | 1,526 | 1,599 | 1,072 | 602 |
Cost of Revenue | |||||
Gross Profit | 698 | 1,128 | 1,140 | 776 | 445 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 801 | 1,310 | 1,414 | 946 | 600 |
Operating Profit | 134 | 216 | 185 | 126 | 2.88 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 134 | 216 | 184 | 129 | 3.79 |
Provision for Income Taxes | |||||
Net Income After Taxes | 103 | 164 | 144 | 99.4 | 2.09 |
Net Income Before Extraordinary Items | |||||
Net Income | 103 | 164 | 144 | 99.4 | 2.09 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 103 | 164 | 144 | 99.4 | 2.09 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 9.14 | 13.9 | 12.7 | 9.1 | 0.82 |
Dividends per Share |